Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock [Yahoo! Finance]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Yahoo! Finance
With its triumphant entry into an unserved market thanks to the approval of its latest medicine, Madrigal can now start to report sales for the first time. Let's take a beat and assess how important this accomplishment is, and how it could benefit investors moving forward. This breakthrough could pay off for years On March 14, the Food and Drug Administration (FDA) signed off on Madrigal's therapy called Rezdiffra, which is the first approved drug that treats metabolic dysfunction-associated steatohepatitis (MASH), a liver-scarring disease formerly known as non-alcoholic steatohepatitis (NASH). The medicine was approved on an accelerated basis, so it's clear that regulators have a good measure of confidence in its efficacy. Approximately 1.5 million people in the U.S. have MASH, and the company can treat somewhere in the ballpark of 315,000 with the approval it currently has. Rezdiffra will start its commercial launch in April, and unless the ongoing confirmatory clinical tria
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Statement on the Passing of Dr. Stephen HarrisonGlobeNewswire
- Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage [Seeking Alpha]Seeking Alpha
- Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024GlobeNewswire
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is now covered by analysts at Bank of America Co.. They set an "underperform" rating and a $150.00 price target on the stock.MarketBeat